Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COAG NASDAQ:IRD NASDAQ:MLTX NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOAGHemab Therapeutics$25.30-0.4%$0.00$23.00▼$36.61$1.18BN/A215,042 shs184,206 shsIRDOpus Genetics$4.03-13.1%$4.83$0.90▼$5.81$377.67M0.56918,976 shs1.02 million shsMLTXMoonLake Immunotherapeutics$17.90-4.4%$17.74$5.95▼$62.75$1.38B1.04925,153 shs538,586 shsURGNUrogen Pharma$26.85-2.7%$24.65$5.23▼$32.37$1.34B1.59747,752 shs685,785 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOAGHemab Therapeutics-2.90%-9.25%+1.64%+2,540,999,900.00%+2,540,999,900.00%IRDOpus Genetics+10.48%+10.48%-10.77%-5.11%+368.69%MLTXMoonLake Immunotherapeutics+2.46%+0.21%+10.05%+3.54%-63.33%URGNUrogen Pharma+3.76%-3.80%+15.82%+34.90%+460.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOAGHemab Therapeutics$25.30-0.4%$0.00$23.00▼$36.61$1.18BN/A215,042 shs184,206 shsIRDOpus Genetics$4.03-13.1%$4.83$0.90▼$5.81$377.67M0.56918,976 shs1.02 million shsMLTXMoonLake Immunotherapeutics$17.90-4.4%$17.74$5.95▼$62.75$1.38B1.04925,153 shs538,586 shsURGNUrogen Pharma$26.85-2.7%$24.65$5.23▼$32.37$1.34B1.59747,752 shs685,785 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOAGHemab Therapeutics-2.90%-9.25%+1.64%+2,540,999,900.00%+2,540,999,900.00%IRDOpus Genetics+10.48%+10.48%-10.77%-5.11%+368.69%MLTXMoonLake Immunotherapeutics+2.46%+0.21%+10.05%+3.54%-63.33%URGNUrogen Pharma+3.76%-3.80%+15.82%+34.90%+460.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOAGHemab Therapeutics 2.80Moderate Buy$41.7565.02% UpsideIRDOpus Genetics 2.88Moderate Buy$10.67164.68% UpsideMLTXMoonLake Immunotherapeutics 2.38Hold$23.8533.22% UpsideURGNUrogen Pharma 2.80Moderate Buy$36.6736.56% UpsideCurrent Analyst Ratings BreakdownLatest IRD, URGN, MLTX, and COAG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026IRDOpus Genetics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/4/2026IRDOpus Genetics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$16.006/3/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.006/2/2026URGNUrogen Pharma OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/27/2026COAGHemab Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/26/2026COAGHemab Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$39.005/26/2026COAGHemab Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.005/26/2026COAGHemab Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$39.005/26/2026COAGHemab Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.005/26/2026COAGHemab Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$50.005/26/2026COAGHemab Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$42.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOAGHemab TherapeuticsN/AN/AN/AN/AN/AN/AIRDOpus Genetics$14.20M23.10N/AN/A$0.22 per share18.32MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/AURGNUrogen Pharma$109.79M11.91N/AN/A($2.25) per share-11.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOAGHemab TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AN/AIRDOpus Genetics-$49.59M-$1.33N/AN/AN/A-892.36%-338.88%-191.21%8/12/2026 (Estimated)MLTXMoonLake Immunotherapeutics-$227.32M-$3.87N/AN/AN/AN/A-85.15%-60.52%8/4/2026 (Estimated)URGNUrogen Pharma-$153.49M-$2.75N/A19.18N/A-94.83%N/A-62.85%8/6/2026 (Estimated)Latest IRD, URGN, MLTX, and COAG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026COAGHemab TherapeuticsN/A-$23.98N/A-$23.98N/AN/A5/12/2026Q1 2026IRDOpus Genetics-$0.16-$0.75-$0.59-$0.75$2.93 million$2.16 million5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91-$0.98-$0.07-$0.98N/AN/A5/7/2026Q1 2026URGNUrogen Pharma-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOAGHemab TherapeuticsN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOAGHemab TherapeuticsN/AN/AN/AIRDOpus GeneticsN/A7.137.13MLTXMoonLake Immunotherapeutics0.398.608.60URGNUrogen PharmaN/A4.694.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOAGHemab TherapeuticsN/AIRDOpus Genetics14.97%MLTXMoonLake Immunotherapeutics93.85%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipCOAGHemab TherapeuticsN/AIRDOpus Genetics11.70%MLTXMoonLake Immunotherapeutics12.02%URGNUrogen Pharma4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOAGHemab Therapeutics7246.71 millionN/AN/AIRDOpus Genetics1481.40 million71.87 millionN/AMLTXMoonLake Immunotherapeutics273.61 million64.77 millionOptionableURGNUrogen Pharma20048.72 million46.43 millionOptionableIRD, URGN, MLTX, and COAG HeadlinesRecent News About These CompaniesUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5 at 8:00 AM | globenewswire.comUroGen settles with Teva over Jelmyto patent disputeJune 3 at 12:21 AM | msn.comUroGen, Teva Settle Jelmyto Patent Dispute, License GenericJune 2 at 8:50 AM | tipranks.comUroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solutionJune 2 at 8:00 AM | globenewswire.comUroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceJune 1, 2026 | globenewswire.comCritical Review: Urogen Pharma (NASDAQ:URGN) vs. Gilead Sciences (NASDAQ:GILD)May 27, 2026 | americanbankingnews.comWhat to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock SurgeMay 24, 2026 | aol.comAHow UGN-103’s Strong Phase 3 UTOPIA Data Could Shape UroGen Pharma (URGN) InvestorsMay 23, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN) and CervoMed (CRVO)May 18, 2026 | theglobeandmail.comUroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer TranscriptMay 17, 2026 | seekingalpha.comUroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBCMay 15, 2026 | globenewswire.comUroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION TrialMay 13, 2026 | globenewswire.comURGN Share News TodayMay 12, 2026 | uk.investing.comUrogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?May 11, 2026 | zacks.comUrogen Pharma (NASDAQ:URGN) Now Covered by Analysts at LADENBURG THALM/SH SHMay 11, 2026 | marketbeat.comAssessing UroGen Pharma (URGN) Valuation After Q1 2026 Earnings Beat And Zusduri Launch MomentumMay 8, 2026 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Q1 2026 Earnings Call TranscriptMay 8, 2026 | insidermonkey.comUrogen Pharma (NASDAQ:URGN) Sets New 1-Year High Following Analyst UpgradeMay 8, 2026 | marketbeat.comUroGen Pharma Earnings Call Highlights ZUSDURI SurgeMay 7, 2026 | tipranks.comUroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027May 7, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?By Jessica Mitacek | May 12, 2026AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in FocusBy Jessica Mitacek | May 26, 2026Why AST SpaceMobile Is the Bigger Winner of the AT&T, T-Mobile, and Verizon Joint VentureBy Jessica Mitacek | May 20, 2026Fifth Third’s Big Bet Is OnBy Peter Frank | June 4, 2026IRD, URGN, MLTX, and COAG Company DescriptionsHemab Therapeutics NASDAQ:COAG$25.30 -0.11 (-0.43%) As of 04:00 PM EasternWe are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.Opus Genetics NASDAQ:IRD$4.03 -0.61 (-13.15%) Closing price 04:00 PM EasternExtended Trading$4.04 +0.01 (+0.25%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.MoonLake Immunotherapeutics NASDAQ:MLTX$17.90 -0.82 (-4.38%) Closing price 04:00 PM EasternExtended Trading$17.93 +0.03 (+0.17%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Urogen Pharma NASDAQ:URGN$26.85 -0.75 (-2.72%) Closing price 04:00 PM EasternExtended Trading$26.55 -0.30 (-1.13%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
